JP4459435B2 - 新規t細胞膜蛋白質(tirc7)、ペプチドおよびそれに由来する抗体ならびにその使用 - Google Patents

新規t細胞膜蛋白質(tirc7)、ペプチドおよびそれに由来する抗体ならびにその使用 Download PDF

Info

Publication number
JP4459435B2
JP4459435B2 JP2000508792A JP2000508792A JP4459435B2 JP 4459435 B2 JP4459435 B2 JP 4459435B2 JP 2000508792 A JP2000508792 A JP 2000508792A JP 2000508792 A JP2000508792 A JP 2000508792A JP 4459435 B2 JP4459435 B2 JP 4459435B2
Authority
JP
Japan
Prior art keywords
cell
tirc7
leu
protein
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000508792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001514852A (ja
JP2001514852A5 (https=
Inventor
ナラン ウトゥク
スティーブン アール. グランス
エドガー エル. ミルフォード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19738710A external-priority patent/DE19738710A1/de
Application filed by Individual filed Critical Individual
Publication of JP2001514852A publication Critical patent/JP2001514852A/ja
Publication of JP2001514852A5 publication Critical patent/JP2001514852A5/ja
Application granted granted Critical
Publication of JP4459435B2 publication Critical patent/JP4459435B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2000508792A 1997-08-29 1998-08-28 新規t細胞膜蛋白質(tirc7)、ペプチドおよびそれに由来する抗体ならびにその使用 Expired - Lifetime JP4459435B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19738710A DE19738710A1 (de) 1997-08-29 1997-08-29 Verwendung von TIRC7 zur Herstellung von Mitteln zur Inhibition der Immunantwort
DE19738710.1 1998-02-12
DE29802653 1998-02-12
DE29802653.8 1998-02-12
PCT/EP1998/005462 WO1999011782A1 (en) 1997-08-29 1998-08-28 T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof

Publications (3)

Publication Number Publication Date
JP2001514852A JP2001514852A (ja) 2001-09-18
JP2001514852A5 JP2001514852A5 (https=) 2006-01-05
JP4459435B2 true JP4459435B2 (ja) 2010-04-28

Family

ID=26039678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000508792A Expired - Lifetime JP4459435B2 (ja) 1997-08-29 1998-08-28 新規t細胞膜蛋白質(tirc7)、ペプチドおよびそれに由来する抗体ならびにその使用

Country Status (10)

Country Link
EP (2) EP0996726B1 (https=)
JP (1) JP4459435B2 (https=)
AT (1) ATE256185T1 (https=)
AU (1) AU751151C (https=)
CA (1) CA2301499C (https=)
DE (1) DE69820449T2 (https=)
DK (1) DK0996726T3 (https=)
ES (1) ES2213295T3 (https=)
PT (1) PT996726E (https=)
WO (1) WO1999011782A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
AU2001263888A1 (en) * 2000-05-03 2001-11-12 Genpat77 Pharmacogenetics Ag Uses of tgap7 for the modulation of leucocyte activation
WO2002036149A2 (en) * 2000-10-30 2002-05-10 Nalan Utku Methods for obtaining inhibitors of t-cell membrane protein (tirc7) ligand binding and uses thereof
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2003025000A2 (en) * 2001-09-17 2003-03-27 Nalan Utku Peptides capable of modulating immune response
US20050118178A1 (en) * 2001-11-27 2005-06-02 Nalan Utku Use of t-cell immune response cdna7 (tirc7) in angiogenic and anti-angiogenic therapy
AU2002366746A1 (en) * 2001-12-21 2003-07-09 Genpat77 Pharmacogenetics Ag Anti-tirc7 antibodies in therapy of inflammatory diseases
US20060165684A1 (en) 2001-12-21 2006-07-27 Nalan Utku Therapeutic anti-tirc7 antibodies for use in immune related and other diseases
JP2005531500A (ja) * 2002-02-04 2005-10-20 ウトゥク ナラン 貪食細胞およびリンパ細胞集団に対する影響を調節するための、tirc7を用いた組成物および方法
WO2003091285A1 (en) * 2002-04-26 2003-11-06 Genpat77 Pharmacogenetics Ag Bispecific molecules for use in therapy and diagnosis of immune related and other diseases
JP2006506954A (ja) * 2002-04-29 2006-03-02 ゲンパト77 ファーマコジェネティクス エージー Tcr及びtirc7に結合する新規な抗体、並びに治療及び診断におけるその使用
US20110183921A1 (en) * 2005-05-17 2011-07-28 Jojomed Gmbh Peptides capable of modulating the function of tirc7
WO2006122791A2 (en) * 2005-05-17 2006-11-23 Genpat77 Pharmacogenetics Ag Tirc7 as marker for detecting early immune activation
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
AU2017309306A1 (en) 2016-08-09 2019-02-28 Nekonal S.A.R.L. TIRC7 based diagnostic and therapy of cancer
EP3497235A1 (en) 2016-08-10 2019-06-19 Nekonal S.A.R.L. Tirc7 based diagnostic and therapy of solid cancer
US20220288120A1 (en) 2019-08-14 2022-09-15 Nekonal S.A.R.L. Method for producing engineered tirc7 specific t-regulatory cells (tregs)

Also Published As

Publication number Publication date
AU751151B2 (en) 2002-08-08
PT996726E (pt) 2004-04-30
DE69820449D1 (de) 2004-01-22
EP0996726B1 (en) 2003-12-10
ATE256185T1 (de) 2003-12-15
AU9265498A (en) 1999-03-22
EP1350848A2 (en) 2003-10-08
WO1999011782A1 (en) 1999-03-11
AU751151C (en) 2006-09-14
DE69820449T2 (de) 2005-03-10
DK0996726T3 (da) 2004-04-13
ES2213295T3 (es) 2004-08-16
EP1350848A3 (en) 2004-02-04
CA2301499A1 (en) 1999-03-11
CA2301499C (en) 2010-01-26
JP2001514852A (ja) 2001-09-18
EP0996726A1 (en) 2000-05-03

Similar Documents

Publication Publication Date Title
JP4459435B2 (ja) 新規t細胞膜蛋白質(tirc7)、ペプチドおよびそれに由来する抗体ならびにその使用
US6338851B1 (en) Method of suppressing an immune response to a transplanted organ or tissue by administering an OX-2 protein
JP4169478B2 (ja) Cd19×cd3特異的ポリペプチドおよびその使用
JP4426724B2 (ja) Ldcamと称される分子
JPH09509826A (ja) 活性化cd4▲上+▼t細胞の表層上のレセプターに対するリガンド(act−4−l)
WO1995017506A9 (en) Mediators of chronic allograft rejection
WO1995017506A1 (en) Mediators of chronic allograft rejection
MXPA04003057A (es) Proteina 4 de enlace ul16.
EP1119253A1 (en) NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
US7863418B2 (en) T-cell membrane protein (TIRC7) and peptides derived therefrom
WO1997021450A1 (en) Ox-2 costimulatory molecule
EP0795014A1 (en) Purified genes encoding mammalian cell surface antigens; proteins and antibodies
WO1995002611A1 (en) Cell surface protein present on nk (natural killer cells) named dx1
US20070212714A1 (en) Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereof
EP1278535B1 (en) Uses of tgap7 for the modulation of leucocyte activation
US20030219424A1 (en) Novel T-cell protein (TZON7), peptides and antibodies derived therefrom and uses thereof
MXPA97003956A (en) Purified genes that codify antigens of surface of mammali cells, proteins and antibody
HK1159128B (en) Novel polypeptides involved in immune response
HK1159128A1 (en) Novel polypeptides involved in immune response
MXPA01007843A (en) Novel polypeptides involved in immune response
HK1159127B (en) Novel polypeptides involved in immune response
HK1160665A (en) Polypeptides involved in immune response

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091007

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100114

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100210

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130219

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140219

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term